skip to primary navigationskip to content

Cambridge Institute for Medical Research

Department A-Z

Our strategy

We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.

Read more

Research advances

Reporting in Nature, the Rubinsztein lab have discovered a role for the poly Q protein ataxin-3 in directly regulating autophagy, which is disrupted in neurodegenerative diseases.

Read more

Research advances

In eLife, the Nathan lab uncover a new pathway linking the V-ATPase proton pump with iron metabolism to regulate stabilization of the hypoxia-inducible transcription factor HIF1a.

Read more

New Royal Society Fellows

Many congratulations to David Rubinsztein and David Owen for their election to the Royal Society.

Read more

Spin-out success

Congratulations to Jim Huntington on the £7 million Series A funding of the spin-out company Z Factor Ltd, which aims to identify drugs for the treatment of alpha-1-antitrypsin deficiency.

Read more

New Wellcome Trust Henry Dale Fellow

Congratulations to Delphine Larrieu, who has been awarded a Dale Fellowship to start her research group this year.

Read more

A unique partnership between basic and clinical research, aiming to understand the cellular basis of disease

New publications


Ron and Marciniak labs (eLife 2017)

Reassessing PPP1R15A regulation.


Rubinsztein lab (Nature 2017)

PolyQ protein control of autophagy.


Reid lab (J. Cell Biol. 2017)

ER-endosome contacts and lysosome function in HSPs.


Ron lab (BMC Biol. 2017)

Tracking ER hydrogen peroxide.


Rubinsztein lab (Brain 2017)

Autophagy upregulation as strategy for tauopathies.


Read lab (PNAS 2017)

Predicting crystal structure success.


Maxwell lab (PLoS Genet. 2017)

Altered mitochondrial RNA translation in kidney disease.